Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (vol 12, pg 74, 2022)-MedSci.cn

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (vol 12, pg 74, 2022)

Janne, PA; Baik, C; Su, WC; Johnson, MI; Hayashi, H; Nishio, M

CANCER DISCOVERY, 2022; 12 (6): 1598

科室
- - 订阅+
  - 更多科室
工具
服务